CEO Werner Baumann: “We want to help people in the affected regions quickly and effectively”
Submitted by Bayer
Bayer is donating medicines and additional financial aid worth a total of approximately EUR 1.5 million to support the population affected by the outbreak of the novel coronavirus in China. The donations will be made to the Chinese Red Cross, which is working together with the health authorities to coordinate the deployment of aid measures for the prevention, diagnosis, treatment and containment of the coronavirus.
“We want to help people in the affected regions quickly and effectively,” said Werner Baumann, Chairman of the Board of Management of Bayer AG. “Our people have worked hard over the Chinese New Year holiday season to make sure that these medicines can be supplied without delay.”
The donated medicines – Avelox® (antibiotic), Redoxon® (vitamin C), Saridon® (antipyretic/analgesic), and Gadovist® and Ultravist® (contrast media) – have a total value of EUR 850,000. The approximately EUR 600,000 cash donation will be used primarily to provide the protective clothing urgently needed by the medical staff in Wuhan.
Medical and monetary donations to help people in need are an integral part of Bayer’s corporate philosophy and commitment to social engagement.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.
Find more information at www.bayer.com.
Follow us on Twitter: twitter.com/BayerPresse_DE
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
More from Bayer